Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET

Journal of Nuclear Medicine

Volumn 43, Issue 10, 2002, Pages 1304-1309

  Hoekstra, Corneline J ^a   Hoekstra, Otto S ^a   Stroobants, Sigrid G ^a   Vansteenkiste, Johan ^a   Nuyts, Johan ^a   Smit, Egbert F ^a   Boers, Maarten ^a   Twisk, Jos W R ^a   Lammertsma, Adriaan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

18F FDG PET; Cancer; Methodology; Response monitoring

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ANALYTIC METHOD; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; GLUCOSE INTAKE; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MALE; MODEL; MONITORING; NONLINEAR REGRESSION ANALYSIS; OBSERVER VARIATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STANDARD;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; REGRESSION ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0036789344     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases - Leuven Lung Cancer Group. Ann Thorac Surg. 1997;63:1441-1450.
2. Misquitta A, Herman S, Winton T, Burkes R, Shepherd F, Rappaport D. Accuracy of CT in predicting prognosis in patients with non-small cell lung carcinoma after induction chemotherapy [abstract]. Radiology. 1994;193:257.
3. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998;91:4464-4471.
4. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verbeken EK. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study - The Leuven Lung Cancer Group. Ann Oncol. 1998;9:1193-1198.
5. MacManus MP, Hicks RJ, Wada M, et al. Early F-18 FDG-PET response to radical chemoradiotherapy correlates strongly with survival in unresectable non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 2000;19:483a.
6. 18F]-D-glucose. Cancer. 1998;82:2227-2234.
7. 18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med. 2000;27:731-743.
8. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer. 1999;35:1773-1782.
9. Boellaard R, van Balen SC, Lammertsma AA. Optimization of attenuation correction for PET studies of thorax and pelvis using count-based transmission scans [abstract]. J Nucl Med. 2001;42(suppl):196P.
10. Hoekstra C, Hoekstra O, Lammertsma AA. On the use of image derived input functions in oncological FDG PET studies. Eur J Nucl Med. 1999;26:1489-1492.
11. 18F-FDG PET scans. J Nucl Med. 2001;42:1622-1629.
12. Boellaard R, van Lingen A, Lammertsma AA. Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling. J Nucl Med. 2001;42:808 -817.
13. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7.
14. Wu HM, Huang SC, Choi Y, Hoh CK, Hawkins RA. A modeling method to improve quantitation of fluorodeoxyglucose uptake in heterogeneous tumor tissue, J Nucl Med. 1995;36:297-306.
15. Zasadny KR, Wahl RL. Enhanced FDG-PET tumor imaging with correlation-coefficient filtered influx-constant images. J Nucl Med. 1996;37:371-374.
16. Wu HM, Hoh CK, Huang SC, Yao WJ, Phelps ME, Hawkins RA. Quantification of serial tumor glucose metabolism. J Nucl Med. 1996;37:506-513.
17. Hunter GJ, Hamberg LM, Alpert NM, Choi NC, Fischman AJ. Simplified measurement of deoxyglucose utilization rate. J Nucl Med. 1996;37:950-955.
18. Sadato N, Tsuchida T, Nakaumra S, et al. Non-invasive estimation of the net influx constant using the standardized uptake value for quantification of FDG uptake of tumours. Eur J Nucl Med. 1998;25:559-564.
19. Akaike H. A new look at the statistical identification. IEEE Trans Automat Contr. 1978;19:716-723.
20. Schwarz G. Estimating the dimension of a model. Ann Statist. 1978;6:461-464.
21. Shrout P, Fleiss J. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420-428.
22. 18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab. 1992;12:823-834.
23. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995;36:1811-1817.
24. Keyes JWJ. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836-1839.
25. Langen KJ, Braun U, Rota KE, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med. 1993;34:355-359.
26. Wahl RL, Henry CA, Ethier SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology. 1992;183:643-647.
27. Kim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med. 1994;35:164-167.